



iTrack™ Advance to be Featured at 35th APACRS Annual Meeting, Singapore

California, USA, June 8, 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that its proprietary iTrack™ technology portfolio for canaloplasty, an implant-free, minimally invasive surgical procedure for glaucoma, will be featured during the official scientific program of the 35th Asia-Pacific Association of Cataract and Refractive Surgery (APACRS) Annual Meeting in Singapore, June 8-10, 2023.

A summary of the iTrack™ scientific paper programming at the APACRS is outlined below:

24-Month Evaluation of Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty using the iTrack™

David Lubeck, MD (USA), Robert Noecker, MD (USA)

Friday, June 9

15:20 - 15:25 (FP4-15)

iTrack™ Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma

David Lubeck, MD (USA), Keith Barton, MD (UK), Iqbal Ike K. Ahmed MD (Canada), Nathan Kerr MD (USA)

Saturday, 10 June

14:35 - 14:40 (FP8-07)

The 35th APACRS Annual Meeting coincides with recent market clearance of the Company's new *iTrack™ Advance* canaloplasty device in Singapore.

"In April 2023 we successfully secured registration of our new *iTrack™ Advance* device in Singapore. Singapore is a key strategic lever in South-East Asia and will support our efforts to drive increased procedural adoption of canaloplasty and the *iTrack™ Advance* throughout the region," commented Nova Eye Medical CEO, Tom Spurling.



“Our team has partnered with several key teaching institutions in Singapore, including the Singapore National Eye Centre (SNEC), National University Hospital (NUH) and Tan Tock Seng Hospital (TTSH) to support the market launch of the *iTrack™ Advance* in Singapore. The APACRS provides a wonderful opportunity to cement these partnerships, and to open dialogue with surgeons throughout the region,” added Mr. Spurling.

Nova Eye Medical will present their leading *iTrack™ Advance* technology and Molteno3® during the APACRS at exhibit #B17, Suntec Convention Centre.

iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the *iTrack™* portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm’s canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm’s canal during the procedure to manually break and remove blockages. Next,



viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance and iTrack™ have US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is not cleared for the ab-interno surgical technique in the United States.

For additional information about the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com/us>

Images are available at this link: <https://bit.ly/3GANwyR>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu